SILVER SPRING, Md.,
Nov. 13, 2013 /PRNewswire/
-- Pharmagen, Inc. (OTCQB: PHRX) (the "Company" or
"Pharmagen") announces it will be participating at the upcoming
Sexual Medicine Society North America (SMSNA) Conference in
New Orleans, LA November 21-23, 2013. The SMSNA seeks to
identify existing and emerging issues in the field of human sexual
function and dysfunction, develop standards and guidelines for
sexual medicine research and practice, and produce educational
program(s) to bring leading-edge concepts of research, clinical
practice, ethics, and politics to health care professionals
interested in sexual medicine.
The Company plans to showcase its vision for the future of
compounding & Urology compliance. Pharmagen looks forward to
promoting its Quality Assurance & Quality Control programs;
including its Rapid ScanRDI Technology, full-time compliance team
and programs to help Urology practices meet their compliance
requirements for office use products.
About Pharmagen
Pharmagen, Inc. ("Pharmagen"),
and wholly owned subsidiaries and operating divisions Pharmagen
Laboratories, Inc., Pharmagen Distribution, LLC and Pharmagen
Nutraceuticals, Inc. offers innovative solutions to the nations
sterile pharmaceutical crisis. With a multi-solution
approach, Pharmagen is helping to meet the demand of the health
provider market through independent wholesale, compounding, and IT
solutions. Nationally focused, Pharmagen is a distributor of
specialty drugs, compounding and admix pharmacy and producer of
over-the-counter ("OTC") branded multivitamins. Pharmagen
currently functions as a just-in-time source of supply for
hospitals for those products that are hard-to-find due to drug
manufacturers' production shortages.
Contact: 888-264-4597 or info@pharmagenrx.com
Follow Us on Twitter: @pharmagenrx or
The Drug Shortage Report
http://drugshortagereport.blogspot.com/
About Kymanox
Kymanox is a premier technical products
and project management services organization. They are experts in
providing clientele in the Biotech, Pharma, Device, and Nano
industries with engineering, scientific, regulatory, and process
operations support.
Safe Harbor Statement
Information in
this document constitute forward-looking statements or statements
which may be deemed or construed to be forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995. The words "forecast", "anticipate", "estimate",
"project", "intend", "expect", "should", "believe", and similar
expressions are intended to identify forward-looking statements.
These forward-looking statements involve, and are subject to
known and unknown risks, uncertainties and other factors which
could cause Pharmagen actual results, performance (financial or
operating) or achievements to differ from the future results,
performance (financial or operating) or achievements expressed or
implied by such forward-looking statements. The risks,
uncertainties and other factors are more fully discussed in
Pharmagen's filings with the U.S. Securities and Exchange
Commission. All forward-looking statements attributable to
Pharmagen herein are expressly qualified in their entirety by the
above-mentioned cautionary statement. Pharmagen disclaims any
obligation to update forward-looking statements contained in this
estimate, except as may be required by law.
SOURCE Pharmagen, Inc.